Michael Morgan
Impact in
- Hematology top 0.2%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Genetics top 1%
- Virus-based gene therapy research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
-
- CRISPR and Genetic Engineering 20
- RNA Interference and Gene Delivery 14
- Protein Degradation and Inhibitors 7
- Oncology 39
- CAR-T cell therapy research 30
- Co-authors
- Axel Schambach (54 shared papers)Christoph Reuter (18 shared papers)Arnold Ganser (30 shared papers)Jürgen Krauter (13 shared papers)Brigitte Schlegelberger (13 shared papers)Gerhard Heil (6 shared papers)Konstanze Döhner (5 shared papers)Lothar Bergmann (2 shared papers)
- Journals
- Blood (10 papers)Human Gene Therapy (9 papers)Cancers (6 papers)Frontiers in Immunology (5 papers)Leukemia (4 papers)
- Partner nations
- GermanyUnited StatesNetherlands
In The Last Decade
Michael Morgan
100 papers receiving 4.9k citations
Michael Morgan's Hit Papers
Peers
Comparison fields: 5 of 103
- Hematology 2.2k
- Genetics 794
- Oncology 1.5k
- Immunology 1.0k
- Molecular Biology 2.5k
Countries citing papers authored by Michael Morgan
This map shows the geographic impact of Michael Morgan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Morgan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Morgan more than expected).
Fields of papers citing papers by Michael Morgan
This network shows the impact of papers produced by Michael Morgan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Morgan. The network helps show where Michael Morgan may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Morgan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 106 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia Hit paper breakdown → | 2008 | 1103 |
| 2 | 2012 | 318 | |
| 3 | 2011 | 276 | |
| 4 | 2000 | 246 | |
| 5 | 1998 | 244 | |
| 6 | 2016 | 225 | |
| 7 | 2003 | 115 | |
| 8 | 2020 | 113 | |
| 9 | 2017 | 111 | |
| 10 | 2001 | 109 | |
| 11 | 2009 | 94 | |
| 12 | 2007 | 88 | |
| 13 | 2019 | 87 | |
| 14 | 2017 | 81 | |
| 15 | 2011 | 80 | |
| 16 | 2020 | 78 | |
| 17 | 2015 | 69 | |
| 18 | 2018 | 64 | |
| 19 | 2016 | 58 | |
| 20 | 2019 | 55 |
About Michael Morgan
Michael Morgan is a scholar working on Molecular Biology, Oncology, Hematology, Genetics and Immunology, having authored 106 papers that have together received 5.0k indexed citations. Recurring topics across this work include CAR-T cell therapy research (30 papers), Virus-based gene therapy research (24 papers), Acute Myeloid Leukemia Research (22 papers), CRISPR and Genetic Engineering (20 papers), Immune Cell Function and Interaction (17 papers), RNA Interference and Gene Delivery (14 papers), Protein Degradation and Inhibitors (7 papers) and T-cell and B-cell Immunology (7 papers). The work is most often cited by research in Hematology (2.2k citations), Genetics (794 citations), Oncology (1.5k citations), Immunology (1.0k citations) and Molecular Biology (2.5k citations). Michael Morgan has collaborated with scholars based in Germany, United States and Netherlands. Frequent co-authors include Axel Schambach, Christoph Reuter, Arnold Ganser, Jürgen Krauter, Brigitte Schlegelberger, Gerhard Heil, Konstanze Döhner, Lothar Bergmann, Hartmut Döhner and Richard F. Schlenk. Their work appears in journals such as Blood, Human Gene Therapy, Cancers, Frontiers in Immunology and Leukemia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.